Overview

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.
Phase:
Phase 4
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Sunovion
Treatments:
Haloperidol
Haloperidol decanoate
Lurasidone Hydrochloride
Perphenazine